Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-21 @ 8:27 PM
Study NCT ID:
NCT03080051
Status:
COMPLETED
Last Update Posted:
2017-10-06
First Post:
2017-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Sponsor:
Molecular NeuroImaging
Organization:
Study Overview
Official Title:
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.
Detailed Description:
The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.
* To characterize \[18F\]MNI-952, a PET radioligand for imaging tau.
* To visually and quantitatively assess brain uptake and pharmacokinetics of \[18F\]MNI-952, a PET imaging marker for tau pathology in individuals with Progressive Supranuclear Palsy (PSP) or Alzheimer's disease (AD) and compare with healthy volunteers (HV).
* To evaluate the safety of a single injection of \[18F\]MNI-952.
* To compare the distribution of tau (using \[18F\]MNI-952) and Aâ (using florbetapir) in AD subjects.
* To characterize \[18F\]MNI-952, a PET radioligand for imaging tau.
* To visually and quantitatively assess brain uptake and pharmacokinetics of \[18F\]MNI-952, a PET imaging marker for tau pathology in individuals with Progressive Supranuclear Palsy (PSP) or Alzheimer's disease (AD) and compare with healthy volunteers (HV).
* To evaluate the safety of a single injection of \[18F\]MNI-952.
* To compare the distribution of tau (using \[18F\]MNI-952) and Aâ (using florbetapir) in AD subjects.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: